RenovoRx Inc.

06/30/2026 | Press release | Distributed by Public on 06/30/2026 14:55

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 30, 2026, RenovoRx, Inc., a Delaware corporation (the "Company"), held its 2026 annual meeting of stockholders (the "Annual Meeting"). The number of shares of common stock, par value $0.0001 per share, of the Company entitled to vote at the Annual Meeting (the "Voting Stock") was 45,052,706 shares outstanding as of May 11, 2026, the record date. No other shares of the Company's capital stock were entitled to vote at the Annual Meeting. The number of shares of Voting Stock present or represented by valid proxy at the Annual Meeting was approximately 22,825,465 shares of Voting Stock, constituting a quorum. At the Annual Meeting, the Company's stockholders voted on the following three proposals:

Proposal 1 - Director Election Proposal

At the Annual Meeting, the Company's stockholders elected each of Shaun R. Bagai, Ramtin Agah, M.D., Kirsten Angela Macfarlane, Laurence J. Marton, M.D., Una S. Ryan, O.B.E., Ph.D., D.Sc., and Robert J. Spiegel, M.D., FACP as a director for a one-year term that expires at the Company's 2027 annual meeting of stockholders or until a successor is duly elected and qualified, subject to his or her earlier death, removal or resignation. The voting results were as follows:

Nominee Votes For Votes Withheld Broker Non-Vote
Shaun R. Bagai 12,954,344 307,353 9,563,768
Ramtin Agah, M.D. 12,954,033 307,664 9,563,768
Kirsten Angela Macfarlane 12,955,760 305,937 9,563,768
Laurence J. Marton, M.D. 12,918,203 343,495 9,563,767
Una S. Ryan, O.B.E., Ph.D., D.Sc. 12,887,870 373,828 9,563,767
Robert J. Spiegel, M.D., FACP 12,963,692 298,006 9,563,767

Proposal 2 - Incentive Plan Amendment Proposal

The Company's stockholders voted to approve an amendment to the Company's Amended and Restated 2021 Omnibus Equity Incentive Plan (the "2021 Plan") to add 2,000,000 shares of common stock of the Company, which is equal to 4.4% of total issued and outstanding shares, to the total number of shares of common stock reserved and available for issuance under such plan. The voting results were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
9,666,218 3,565,088 30,391 9,563,768

The form of 2021 Plan as amended to reflect the amendment is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Proposal 3 - Auditor Ratification Proposal

The Company's stockholders voted to ratify the appointment by the audit committee of the Board of Directors of the Company of Frank, Rimerman + Co. LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows:

Votes For Votes Against Abstentions Broker Non-Votes
21,938,316 477,181 409,966 2
RenovoRx Inc. published this content on June 30, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on June 30, 2026 at 20:55 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]